Amarin Corp
Research Amarin Corp (AMRN) on Bullrun: market cap USD 297.18M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAMRN
- ExchangeNASDAQ
- CountryIreland
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Market capUSD 297.18M
- Financial periodQ2 2026
- RevenueUSD 42.21M
- Net income-USD 7.65M
- Free cash flowUSD 6.60M
- Gross margin35.5%
Valuation Snapshot
latest market cap is USD 297.18M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 213.65M | -USD 38.80M | USD 6.73M | 56.6% | -0.09 | USD 134.66M | USD 6.08M | USD 459.28M |
| FY2024 | USD 228.61M | -USD 87.00M | -USD 31.02M | 35.6% | -0.2 | USD 121.04M | USD 7.72M | USD 486.18M |
| FY2023 | USD 306.91M | -USD 55.00M | USD 6.35M | 53.9% | -0.15 | USD 199.25M | USD 8.74M | USD 552.10M |
| FY2022 | USD 369.19M | -USD 105.80M | n/a | 65.7% | -0.26 | USD 217.67M | USD 10.17M | USD 595.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 297.18M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 290.52M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 201.68M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 355.21M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 488.63M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.34B | 3370.0 | n/a | n/a |
About Amarin Corp
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Amarin Corp's market cap?
Amarin Corp's market capitalization is USD 297.18M.
What does Amarin Corp do?
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd.